A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells
- PMID: 15908423
- DOI: 10.1074/jbc.M505203200
A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells
Abstract
In cancer cells, the function of the tumor suppressor protein p53 is usually blocked. Impairment of the p53 pathway results in tumor cells with endogenous overexpression of Mdm2 via a naturally occurring single nucleotide polymorphism (SNP) in the mdm2 gene at position 309. Here we report that in mdm2 SNP309 cells, inactivation of p53 results in a chromatin-associated Mdm2-p53 complex without clearance of p53 by protein degradation. Nuclear accumulation of p53 protein in mdm2 SNP309 cells results after 6 h of camptothecin, etoposide, or mitomycin C treatment, with the p53 protein phosphorylated at Ser15. Chromatin immunoprecipitation demonstrated p53 and Mdm2 bound to p53 responsive elements. Interestingly, although the p53 protein was able to bind to DNA, quantitative PCR showed compromised transcription of endogenous target genes. Additionally, exogenously introduced p53 was incapable of activating transcription from p53 responsive elements in SNP309 cells, confirming the trans-acting nature of the inhibitor. Inhibition of Mdm2 by siRNA resulted in transcriptional activation of these p53 targets. Our data suggest that overproduction of Mdm2, resulting from a naturally occurring SNP, inhibits chromatin-bound p53 from activating the transcription of its target genes.
Similar articles
-
Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death.Oncotarget. 2015 Oct 27;6(33):34573-91. doi: 10.18632/oncotarget.5312. Oncotarget. 2015. PMID: 26416444 Free PMC article.
-
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.Cell. 2004 Nov 24;119(5):591-602. doi: 10.1016/j.cell.2004.11.022. Cell. 2004. PMID: 15550242
-
Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes.Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-1-8. Ethn Dis. 2008. PMID: 18646312 Free PMC article.
-
Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.Mol Cancer Res. 2004 Jan;2(1):20-8. Mol Cancer Res. 2004. PMID: 14757842 Review.
-
A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation.Cell Cycle. 2005 Mar;4(3):411-7. doi: 10.4161/cc.4.3.1522. Epub 2005 Mar 2. Cell Cycle. 2005. PMID: 15684615 Review.
Cited by
-
Splicing up mdm2 for cancer proteome diversity.Genes Cancer. 2012 Mar;3(3-4):311-9. doi: 10.1177/1947601912455323. Genes Cancer. 2012. PMID: 23150764 Free PMC article.
-
MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output.EMBO J. 2010 Aug 4;29(15):2538-52. doi: 10.1038/emboj.2010.140. Epub 2010 Jun 29. EMBO J. 2010. PMID: 20588255 Free PMC article.
-
Endogenous human MDM2-C is highly expressed in human cancers and functions as a p53-independent growth activator.PLoS One. 2013 Oct 11;8(10):e77643. doi: 10.1371/journal.pone.0077643. eCollection 2013. PLoS One. 2013. PMID: 24147044 Free PMC article.
-
Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast.BMC Cancer. 2008 Dec 11;8:364. doi: 10.1186/1471-2407-8-364. BMC Cancer. 2008. PMID: 19077243 Free PMC article.
-
Clinical significance of TP53 (R72P) and MDM2 (T309G) polymorphisms in breast cancer patients.Clin Transl Oncol. 2016 Jul;18(7):728-34. doi: 10.1007/s12094-015-1425-5. Epub 2015 Nov 9. Clin Transl Oncol. 2016. PMID: 26553387
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous